Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
BeOne Medicines
Eli Lilly and Company
Terremoto Biosciences Inc.
Blueprint Medicines Corporation
Avenzo Therapeutics, Inc.
AstraZeneca